Close Menu

OncoDNA

Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.

Belgium-based OncoDNA will purchase France's IntegraGen as part of its plans to provide a solution that combines oncology laboratory testing and bioinformatics software.

The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.

The program, which includes OncoDNA, will evaluate the use of molecular diagnostic testing in personalizing treatments for cancer patients in Luxembourg.

OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.

A brief recap of Genetics/Genomics news the week of Oct 5, 2018: OncoDNA, Interpace Diagnostics, B. Braun Melsungen & CeGat, and Premaitha

Genesis Genome will exclusively make available to physicians in Malaysia OncoDNA's OncoDeep Dx and Clinical cancer panels combined with its Package Plus.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.